IV Solutions
0.9% Sodium Chloride Injection, USP, in Fleboflex plastic container
Partners in excellence
Delivering a safe, reliable, and convenient IV solution
0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment in the Fleboflex® plastic container for intravenous administration.
Product overview
- Fleboflex® is a flexible container free of PVC, plasticizers, adhesives, and latex
- The Fleboflex® container consists of a polypropylene multilayer film
- Polypropylene is a highly compatible material. It is used for the preparation of intravenous mixtures with drugs that have shown their incompatibility with other plastics
- Fleboflex® is totally collapsible, lightweight, and transparent
- The Fleboflex® container meets the Class VI US Pharmacopeia (USP) testing for plastic containers. These tests confirm the biological safety of the container system
- Available in 50, 100, 250, 500, and 1000 mL
Fleboflex®
Max. additive volume in mL up to a pressure of 50 mL bar
- 50 mL
-
90
- 100 mL
-
8
- 250 mL
-
135
- 500 mL
-
288
- 1000 mL
-
176
Maximum removable volume (mL)
- 50 mL
-
145
- 100 mL
-
195
- 250 mL
-
397
- 500 mL
-
716
- 1000 mL
-
1207
Residual volume (mL)
- 50 mL
-
0-1
- 100 mL
-
0.3
- 250 mL
-
0.6 - 1.6
- 500 mL
-
0.6 - 7.1
- 1000 mL
-
0.6 - 5
Air volume (mL)
- 50 mL
-
4-10
- 100 mL
-
5-12
- 250 mL
-
5-15
- 500 mL
-
12-25
- 1000 mL
-
15-25
| Fleboflex® | 50 mL | 100 mL | 250 mL | 500 mL | 1000 mL |
|---|---|---|---|---|---|
|
Max. additive volume in mL up to a pressure of 50 mL bar |
90 |
8 |
135 |
288 |
176 |
|
Maximum removable volume (mL) |
145 |
195 |
397 |
716 |
1207 |
|
Residual volume (mL) |
0-1 |
0.3 |
0.6 - 1.6 |
0.6 - 7.1 |
0.6 - 5 |
|
Air volume (mL) |
4-10 |
5-12 |
5-15 |
12-25 |
15-25 |
Drug
Cefotaxime
- Composition
-
0.5 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
1 days
Cefuroxime
- Composition
-
0.5 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
1 days
Cyclophosphamide
- Composition
-
2 mL in 0.9% SC
- 5 °C (41 °F)†
-
6 days
- 25 °C (77 °F)†
-
5 days
Diazepam
- Composition
-
50 μg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
4 days
Docetaxel
- Composition
-
0.3 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
7 days
- 25 °C (77 °F)†
-
7 days
Doxorubicin
- Composition
-
0.1 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
30 days
- 25 °C (77 °F)†
-
15 days
Etoposide
- Composition
-
0.3 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
-
- 25 °C (77 °F)†
-
10 days
5-fluorouracil
- Composition
-
3 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
28 days
- 25 °C (77 °F)†
-
28 days
Isosorbide Dinitrate
- Composition
-
0.1 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
10 days
Methylprednisolone
- Composition
-
5 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
Free Prednisolone >6.6 days
Morphine
- Composition
-
0.1 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
10 days
Nitroglycerin
- Composition
-
50 μg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
10 days
Ondansetron
- Composition
-
1 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
10 days
- 25 °C (77 °F)†
-
10 days
Paclitaxel
- Composition
-
0.6 mg/mL in 0.9% SC
- 5 °C (41 °F)†
-
7 days
- 25 °C (77 °F)†
-
7 days
| Drug | Composition | 5 °C (41 °F)† | 25 °C (77 °F)† |
|---|---|---|---|
|
Cefotaxime |
0.5 mg/mL in 0.9% SC |
10 days |
1 days |
|
Cefuroxime |
0.5 mg/mL in 0.9% SC |
10 days |
1 days |
|
Cyclophosphamide |
2 mL in 0.9% SC |
6 days |
5 days |
|
Diazepam |
50 μg/mL in 0.9% SC |
10 days |
4 days |
|
Docetaxel |
0.3 mg/mL in 0.9% SC |
7 days |
7 days |
|
Doxorubicin |
0.1 mg/mL in 0.9% SC |
30 days |
15 days |
|
Etoposide |
0.3 mg/mL in 0.9% SC |
- |
10 days |
|
5-fluorouracil |
3 mg/mL in 0.9% SC |
28 days |
28 days |
|
Isosorbide Dinitrate |
0.1 mg/mL in 0.9% SC |
10 days |
10 days |
|
Methylprednisolone |
5 mg/mL in 0.9% SC |
10 days |
Free Prednisolone >6.6 days |
|
Morphine |
0.1 mg/mL in 0.9% SC |
10 days |
10 days |
|
Nitroglycerin |
50 μg/mL in 0.9% SC |
10 days |
10 days |
|
Ondansetron |
1 mg/mL in 0.9% SC |
10 days |
10 days |
|
Paclitaxel |
0.6 mg/mL in 0.9% SC |
7 days |
7 days |
Bag features
1
Designed for safe and easy handling
- Designed with rounded upper and lower corners that guarantee handling without accidental punctures
- Integrated eyelet support for easy and safe handling of the container during the infusion
2
Highly compatible material
- The solution is only in contact with polypropylene. Both the multilayer film and the inner membranes of the medication and outlet ports contain only polypropylene
- Polypropylene can be sterilized at a higher temperature because it resists heat better than other olefins
3
High sealing resistance
High resistance to pressure cuffs, responding satisfactorily to 400 mmHg pressure for 72 hours.
4
Product information
- Inclusion of the National Drug Code
- Inclusion of lot and expiration date
5
Grifols port system
- Medication and outlet ports designed with rigid and long tubes to avoid perforation due to needle insertion
- Safe attachment of the infusion set due to its internal membrane
- No parts of the cover have to be removed in order to access the outlet port
Individual overwrap of polypropylene protects and maintains the sterility of the container and limits evaporative moisture loss from the primary solution container. It is transparent to allow visual inspection and has a peelable opening system.
Product also available in Canada
Description
0.9% Sodium Chloride Injection,
USP 50 mL
- NDC Number
-
76297-001-11
- Case weight Kg
-
8
- Bags/ box
-
115
- Bags/ pallet
-
3680
- Bags/ container*
-
169,280
0.9% Sodium Chloride Injection,
USP 100 mL
- NDC Number
-
76297-001-21
- Case weight Kg
-
8.5
- Bags/ box
-
70
- Bags/ pallet
-
2240
- Bags/ container*
-
103,040
0.9% Sodium Chloride Injection,
USP 250 mL
- NDC Number
-
76297-001-31
- Case weight Kg
-
8.5
- Bags/ box
-
28
- Bags/ pallet
-
896
- Bags/ container*
-
41,216
0.9% Sodium Chloride Injection,
USP 500 mL
- NDC Number
-
76297-001-01
- Case weight Kg
-
11.6
- Bags/ box
-
20
- Bags/ pallet
-
640
- Bags/ container*
-
29,440
0.9% Sodium Chloride injection,
USP 1000 mL
- NDC Number
-
76297-001-41
- Case weight Kg
-
11
- Bags/ box
-
10
- Bags/ pallet
-
320
- Bags/ container*
-
14,720
| Description | NDC Number | Case weight Kg | Bags/ box | Bags/ pallet | Bags/ container* |
|---|---|---|---|---|---|
|
0.9% Sodium Chloride Injection, |
76297-001-11 |
8 |
115 |
3680 |
169,280 |
|
0.9% Sodium Chloride Injection, |
76297-001-21 |
8.5 |
70 |
2240 |
103,040 |
|
0.9% Sodium Chloride Injection, |
76297-001-31 |
8.5 |
28 |
896 |
41,216 |
|
0.9% Sodium Chloride Injection, |
76297-001-01 |
11.6 |
20 |
640 |
29,440 |
|
0.9% Sodium Chloride injection, |
76297-001-41 |
11 |
10 |
320 |
14,720 |
Guidelines for use of 0.9% Sodium Chloride solution in Fleboflex® container
Overwrap removal
- The overwrap is designed to be opened by pulling apart the 2 sheets of the overwrap.
- The recommended method to remove the overwrap is to peel off one sheet by the corner while holding the other sheet at one end to carefully remove the solution container.
The overwrap should not be removed until product is to be used.
To add medication
- Prepare the medication site. Using a syringe with a 19- to 22-gauge needle, securely hold the container and insert the needle through the center of the medication port and inject the medication. Insert the needle perpendicular to the point of addition.
The compatibility of the additives with Sodium Chloride 0.9% must be checked before adding a medication.
Attach administration set
- Suspend the container from the eyelet support and remove the protector from the outlet port at the bottom of the container.
- Hold the container properly and attach the administration set.
- While advancing through the tube, a slight resistance will gradually be felt.
Use non-vented administration sets
The Fleboflex® container has been designed to work without venting. No air is required to withdraw the solution.
Air entering through the administration set could slow or even stop the infusion due to air bubbles.
- After opening the container, the contents should be used immediately and should not be stored for a subsequent infusion. Do not reconnect any partially used containers. Discard any unused portion.
Administration sets should come without air venting. If vented administration sets are used, be sure air venting inlet remains closed during the infusion.
Do not connect flexible plastic containers in a series in order to avoid air embolism due to possible residual air contained in the primary container. Using a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers.
Do you have any questions or concerns?
Contact a Grifols representative for more information